Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Liabilities and Shareholders Equity: 2022-2025

Historic Liabilities and Shareholders Equity for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $669.2 million.

  • Axsome Therapeutics' Liabilities and Shareholders Equity rose 19.20% to $669.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 10.28%. This contributed to the annual value of $568.5 million for FY2024, which is 3.36% down from last year.
  • Axsome Therapeutics' Liabilities and Shareholders Equity amounted to $669.2 million in Q3 2025, which was up 4.61% from $639.8 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $669.2 million for Q3 2025, and its period low was $88.6 million during Q1 2022.
  • In the last 3 years, Axsome Therapeutics' Liabilities and Shareholders Equity had a median value of $588.2 million in 2023 and averaged $574.5 million.
  • Per our database at Business Quant, Axsome Therapeutics' Liabilities and Shareholders Equity skyrocketed by 339.45% in 2023 and then dropped by 10.37% in 2024.
  • Axsome Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $331.5 million in 2022, then spiked by 77.46% to $588.2 million in 2023, then dropped by 3.36% to $568.5 million in 2024, then climbed by 19.20% to $669.2 million in 2025.
  • Its last three reported values are $669.2 million in Q3 2025, $639.8 million for Q2 2025, and $596.7 million during Q1 2025.